317 related articles for article (PubMed ID: 17154672)
1. Pulmonary involvement in systemic sclerosis.
Shahin AA
Treat Respir Med; 2006; 5(6):429-36. PubMed ID: 17154672
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
3. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
4. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
5. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sobanski V; Launay D; Hachulla E; Humbert M
Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
7. Bosentan in systemic sclerosis.
Heresi GA; Minai OA
Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
Ramirez A; Varga J
Treat Respir Med; 2004; 3(6):339-52. PubMed ID: 15658881
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
11. [Systemic sclerosis].
Legendre P; Mouthon L
Rev Prat; 2017 Sep; 67(7):775-783. PubMed ID: 30512777
[TBL] [Abstract][Full Text] [Related]
12. [Pulmonary arterial hypertension and systemic sclerosis].
Launay D; Humbert M; Hachulla E
Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
[TBL] [Abstract][Full Text] [Related]
13. The heart and pulmonary arterial hypertension in systemic sclerosis.
Vandecasteele EH; De Pauw M; Brusselle G; Decuman S; Piette Y; De Keyser F; Smith V
Acta Clin Belg; 2016 Feb; 71(1):1-18. PubMed ID: 27075793
[TBL] [Abstract][Full Text] [Related]
14. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
15. The relevance of high-resolution computed tomographic findings and pulmonary arterial hypertension in systemic sclerosis-associated interstitial lung disease.
Wangkaew S; Euathrongchit J; Patiwetwitoon S; Prasertwitayakij N; Kasitanon N; Louthrenoo W
J Med Assoc Thai; 2014 Aug; 97(8):878-85. PubMed ID: 25345265
[TBL] [Abstract][Full Text] [Related]
16. [Heart involvement in systemic sclerosis: analysis of four cases].
Wielosz E; Borys O; Błaszczak P; Majdan M
Ann Acad Med Stetin; 2012; 58(1):33-9; discussion 39. PubMed ID: 23547392
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic challenges for systemic sclerosis: facts and future targets.
Cerinic Matucci M; Del Rosso A; Federico P; Livi R; Fiori G; Bartoli F; Blagojevic J; Tempestini A; Pignone A
Ann N Y Acad Sci; 2007 Sep; 1110():448-54. PubMed ID: 17911460
[TBL] [Abstract][Full Text] [Related]
18. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
19. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
20. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.
Murdaca G; Spanò F; Puppo F
Expert Opin Drug Saf; 2014 Mar; 13(3):295-305. PubMed ID: 24387049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
